Fidelity Investments’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-274,962
| Closed | -$60.7M | – | 5446 |
|
|
2025
Q4 | $60.7M | Sell |
274,962
-500,571
| -65% | -$80.9M | ﹤0.01% | 1361 |
|
|
2025
Q3 | $74.3M | Buy |
775,533
+666,815
| +613% | +$42.6M | ﹤0.01% | 1299 |
|
|
2025
Q2 | $5.3M | Buy |
+108,718
| New | +$2.61M | ﹤0.01% | 2150 |
|
|
2021
Q1 | – | Sell |
-50
| Closed | -$2K | – | 4014 |
|
|
2020
Q4 | $2K | Buy |
+50
| New | +$2.49K | ﹤0.01% | 3571 |
|
|
2018
Q4 | – | Sell |
-44,969
| Closed | -$3.96M | – | 3558 |
|
|
2018
Q3 | $3.96M | Sell |
44,969
-28,609
| -39% | -$2.52M | ﹤0.01% | 2224 |
|
|
2018
Q2 | $7.65M | Hold |
73,578
| – | – | ﹤0.01% | 2027 |
|
|
2018
Q1 | $5.89M | Hold |
73,578
| – | – | ﹤0.01% | 2105 |
|
|
2017
Q4 | $10M | Hold |
73,578
| – | – | ﹤0.01% | 1955 |
|
|
2017
Q3 | $11.9M | Hold |
73,578
| – | – | ﹤0.01% | 1885 |
|
|
2017
Q2 | $11M | Hold |
73,578
| – | – | ﹤0.01% | 1912 |
|
|
2017
Q1 | $11.5M | Hold |
73,578
| – | – | ﹤0.01% | 1921 |
|
|
2016
Q4 | $15.3M | Buy |
73,578
+3,750
| +5% | +$779K | ﹤0.01% | 1796 |
|
|
2016
Q3 | $16M | Hold |
69,828
| – | – | ﹤0.01% | 1783 |
|
|
2016
Q2 | $14.4M | Sell |
69,828
-16,415
| -19% | -$3.97M | ﹤0.01% | 1810 |
|
|
2016
Q1 | $21.9M | Sell |
86,243
-12,077
| -12% | -$2.78M | ﹤0.01% | 1620 |
|
|
2015
Q4 | $33.7M | Sell |
98,320
-2,741
| -3% | -$823K | ﹤0.01% | 1425 |
|
|
2015
Q3 | $25.7M | Hold |
101,061
| – | – | ﹤0.01% | 1552 |
|
|
2015
Q2 | $28.3M | Buy |
+101,061
| New | +$31.1M | ﹤0.01% | 1589 |
|
Fidelity Investments's CDTX Position: Q1 2026 in Review
Fidelity Investments sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 274,962 shares — an estimated $60.7M sold.
Fidelity Investments first reported a position in CDTX in Q2 2015 and held it in 18 quarters. The position peaked at $74.3M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Fidelity Investments reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Fidelity Investments sold 274,962 Cidara Therapeutics shares in Q1 2026, an estimated $60.7M.
- Fidelity Investments first reported a position in Cidara Therapeutics in Q2 2015 and held it in 18 quarters.
- Fidelity Investments's Cidara Therapeutics position peaked at $74.3M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.